Form 8-K - Current report:
SEC Accession No. 0001213900-25-009477
Filing Date
2025-02-03
Accepted
2025-02-03 16:45:33
Documents
13
Period of Report
2025-01-28
Items
Item 3.02: Unregistered Sales of Equity Securities
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0229695-8k_tffphar.htm   iXBRL 8-K 35342
  Complete submission text file 0001213900-25-009477.txt   211316

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE tffp-20250128.xsd EX-101.SCH 3018
3 XBRL LABEL FILE tffp-20250128_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE tffp-20250128_pre.xml EX-101.PRE 22361
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0229695-8k_tffphar_htm.xml XML 3807
Mailing Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746
Business Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746 737-802-1973
TFF Pharmaceuticals, Inc. (Filer) CIK: 0001733413 (see all company filings)

EIN.: 824344737 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39102 | Film No.: 25583241
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)